Neoleukin Therapeutics, Inc. — Q3 2022 Form 10-Q
Entity note: The request identifies Neurogene Inc., but the supplied filing is for Neoleukin Therapeutics, Inc. This summary covers Neoleukin’s unaudited quarter and nine months ended September 30, 2022. The filing describes a pre-revenue biopharmaceutical company developing de novo protein therapies. Subsequent events through November 12, 2022 are also disclosed.
Financial highlights
| Metric | Q3 2022 / September 30, 2022 | Comparable period / change |
|---|---|---|
| Revenue | No product revenue reported | Company had not generated product revenue |
| Research and development | $9.5 million | Down 4% from $9.9 million in Q3 2021 |
| General and administrative | $4.1 million | Down 26% from $5.6 million in Q3 2021 |
| Total operating expenses | $13.6 million | Down 12% from $15.5 million in Q3 2021 |
| Net loss | $13.1 million; $0.24 per share | Versus $15.4 million; $0.28 per share in Q3 2021 |
| Nine-month net loss | $44.1 million | Versus $45.5 million in 2021 |
| Cash, cash equivalents and short-term investments | $106.9 million | At September 30, 2022, versus $142.5 million in cash and cash equivalents at December 31, 2021; no short-term investments then |
| Operating cash use | $34.7 million for nine months | Versus $35.4 million in the prior-year period |
| Working capital | $98.6 million | As of September 30, 2022 |
| Accumulated deficit | $437.6 million | As of September 30, 2022 |
Interest income was $559,000 in Q3 2022 and $766,000 for the first nine months, substantially above 2021, reflecting higher interest rates and purchases of U.S. Treasury securities. The company reported a $92,000 unrealized loss on available-for-sale securities for the nine months. No conventional borrowings are listed; liabilities include operating and finance lease obligations totaling approximately $12.1 million. Operating margins are not meaningful for this pre-revenue company.
Material changes and business developments
- For the first nine months, R&D expense rose 6% to $31.1 million, mainly due to NL-201 Phase 1 trial costs, partly offset by lower personnel and NL-CVX1 costs. G&A expense fell 15% to $13.7 million, primarily due to lower personnel and facility costs.
- Cash, cash equivalents and short-term investments totaled $106.9 million. The company used $34.7 million in operating activities. Investing cash use was $67.6 million, primarily reflecting purchases of Treasury securities and laboratory equipment; securities purchases and maturities should be distinguished from operating burn.
- On November 12, 2022, after quarter-end, the board decided to discontinue NL-201 and concentrate investment on early-stage preclinical development of next-generation de novo proteins, including targeted or conditionally activated molecules. The company said preliminary NL-201 monotherapy data showed target engagement and expected pharmacodynamic changes, without significant immunogenicity observed after multiple cycles, but management judged further development’s expected benefit-risk and resource demands insufficient to justify continuation.
- The board approved a restructuring including an approximately 40% workforce reduction. Estimated costs are $6.3–$8.3 million, including approximately $1.1 million of non-cash expenses; most are expected in Q4 2022 and the first half of 2023, with completion substantially expected by Q2 2023. Actual costs may differ, and additional costs may arise.
- Management stated that, following the strategic shift and expected savings, cash runway is expected to extend into the second half of 2025. This is a forward-looking estimate and depends on assumptions and spending plans.
- The company received Nasdaq notice on October 26, 2022 that its share price had been below the $1 minimum for 30 consecutive trading days; the stated initial compliance deadline was April 24, 2023.
Outlook, risks and other matters
Neoleukin expects ongoing losses and says it may need additional capital; it reported no approved products and, following the NL-201 decision, no candidate then in clinical testing. Management’s runway estimate is subject to uncertainty, and the company may need financing sooner than expected. Potential equity or debt financing could dilute shareholders or impose restrictive terms. Key risks include early-stage pipeline and technology uncertainty, clinical and regulatory failure, reliance on third-party manufacturers and research providers, supply-chain and inflationary pressures, competition, intellectual-property protection, and retention of key personnel during the restructuring.
The company stated that it was not party to legal proceedings expected by management to have a material adverse effect. Disclosure controls and procedures were assessed as effective at a reasonable assurance level, and no materially affecting change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Neoleukin Therapeutics, not Neurogene Inc.
- Track execution and actual costs of the NL-201 discontinuation and workforce reduction against the $6.3–$8.3 million estimate and Q2 2023 completion target.
- Assess whether the revised preclinical strategy can produce validated candidates and whether management’s cash-runway estimate into the second half of 2025 remains supportable.
- Monitor cash burn, liquidity, any need for additional financing, and Nasdaq’s minimum-bid-price compliance status.
- Review potential dilution: 12,663,010 pre-funded warrants were outstanding, and the company had an unused ATM facility permitting up to $40 million in common-stock sales.